OrthoPediatrics CEO sells shares for tax withholding

OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share.

Rhea-AI Filing Summary

OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations triggered when restricted stock vested, rather than as a discretionary portfolio move.

After this transaction, Bailey directly holds 298,020 shares of OrthoPediatrics common stock, which includes 187,891 shares of restricted stock awards. The sale represents only a portion of his overall equity position in the company.

Insider Trade Summary

Net Seller: 19,535 shares

Net Sell 1 txn

Insider Bailey David R

Role President and CEO

Sold 19,535 shs ($337K)

Type	Security	Shares	Price	Value
Sale	Common Stock	19,535	$17.25	$337K

Holdings After Transaction: Common Stock — 298,020 shares (Direct)

Footnotes (2)

1. F1. Shares sold to satisfy tax withholding obligations upon vesting of restricted shares.
2. F2. Includes restricted stock awards totaling 187,891 shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OrthoPediatrics (KIDS) CEO David Bailey do in this insider transaction?

David R. Bailey sold 19,535 OrthoPediatrics shares at $17.25 each. The sale was specifically to cover tax withholding obligations tied to vesting restricted stock, rather than a discretionary reduction of his investment position.

How many OrthoPediatrics (KIDS) shares did the CEO sell and at what price?

The CEO sold 19,535 shares of OrthoPediatrics common stock at $17.25 per share. This transaction was disclosed as an open-market sale undertaken to satisfy tax withholding on recently vested restricted stock awards.

Why were OrthoPediatrics (KIDS) shares sold by the CEO in this filing?

The filing states the shares were sold to satisfy tax withholding obligations when restricted shares vested. This means the transaction was driven by tax requirements associated with compensation, not by an ordinary investment or trading decision.

How many OrthoPediatrics (KIDS) shares does the CEO hold after this transaction?

Following the sale, David R. Bailey directly holds 298,020 OrthoPediatrics shares. This total includes restricted stock awards amounting to 187,891 shares, leaving him with a substantial continuing equity stake in the company.

Does this OrthoPediatrics (KIDS) CEO sale indicate a large change in his ownership?

The transaction involved 19,535 shares sold to cover tax withholding. After the sale, Bailey still holds 298,020 shares, including 187,891 restricted shares, so his overall ownership remains significant despite the tax-related disposition.

What type of transaction was reported for OrthoPediatrics (KIDS) CEO David Bailey?

The report shows an open-market sale of common stock coded as an “S” transaction. Footnotes clarify the sale’s purpose was to meet tax withholding obligations on vested restricted stock, rather than an ordinary voluntary share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey David R

(Last) (First) (Middle)

C/O ORTHOPEDIATRICS CORP.

2850 FRONTIER DRIVE

(Street)

WARSAW IN 46582

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORTHOPEDIATRICS CORP [ KIDS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S		19,535(1)	D	$17.25	298,020(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy tax withholding obligations upon vesting of restricted shares.

2. Includes restricted stock awards totaling 187,891 shares.

Remarks:

	/s/ Daniel J. Gerritzen, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.